Clinical Trial Update: Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a Alloimmunization [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the pharmacokinetics and safety of RLYB212 in pregnant women at high risk for HPA-1a alloimmunization (fetal and neonatal alloimmune th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fetal and Neonatal Alloimmune Thrombocytopenia

Drugs mentioned

• RLYB212

Snippet

Sponsor: Rallybio | Conditions: Fetal and Neonatal Alloimmune Thrombocytopenia | Phase 2 | Status: TERMINATED | Results posted: 2026-03-06